SCHEMBL624642

SCHEMBL624642

CCN1C(=O)c2cccc(Oc3cccc(C)c3C)c2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 4/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
USP2 O75604 1/20 0.43
ATM Q13315 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
CASP1 P29466 1/20 0.39
MPI P34949 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15333870 0.87 CYP1B1 (0.46) CYP1B1SMN1; SMN2TDP1KMT2AHPGD
SCHEMBL12235632 0.80 CYP1B1 (0.58) CYP1B1SMN1; SMN2KMT2AHPGDMEN1
SCHEMBL12235607 0.79 CYP1B1 (0.53) CYP1B1SMN1; SMN2TDP1KMT2AHPGD
SCHEMBL29226173 0.77 HSPA1A (0.52) SMN1; SMN2KMT2AHPGDMEN1USP2
SCHEMBL261589 0.77 TDP1 (0.71) CYP1B1SMN1; SMN2TDP1KMT2AHPGD
SCHEMBL262671 0.75 MEN1 (0.47) SMN1; SMN2TDP1KMT2AHPGDMEN1
SCHEMBL12235606 0.74 TDP2 (0.48) CYP1B1SMN1; SMN2KMT2AHPGDMEN1
SCHEMBL29377898 0.71 MAPT (0.54) SMN1; SMN2KMT2AMEN1NPC1TSHR
SCHEMBL1538371 0.71 MAPT (0.54) SMN1; SMN2KMT2AMEN1NPC1TSHR
SCHEMBL9397152 0.71 CYP1B1 (0.50) CYP1B1SMN1; SMN2TDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 US disclosed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 US disclosed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 US disclosed
US-9238640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2016-01-19 US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP1B1 1961/4885SMN1; SMN2 4234/4885TDP1 2692/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 CYP1B1 2034/4885SMN1; SMN2 3917/4885TDP1 2627/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 CYP1B1 2034/4885SMN1; SMN2 3917/4885TDP1 2627/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP1B1 1961/4885SMN1; SMN2 4234/4885TDP1 2692/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 CYP1B1 1961/4885SMN1; SMN2 4234/4885TDP1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.